Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | SCN2B | O60939 | 3/20 | 0.41 |
| ▸ | SCN1B | Q07699 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PLK4 | O00444 | 4/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083584 | 0.91 | HPGDS (0.74) | HPGDSSCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL12084086 | 0.86 | HPGDS (0.62) | HPGDSSCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL12083923 | 0.86 | HPGDS (0.54) | HPGDSPTGS2PLK4PAK4NTRK1 | |
| SCHEMBL14313075 | 0.86 | HPGDS (0.46) | HPGDSSCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL12083808 | 0.85 | HPGDS (0.63) | HPGDS | |
| SCHEMBL3226414 | 0.83 | HPGDS (0.59) | HPGDSSCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL12084155 | 0.83 | HPGDS (0.60) | HPGDS | |
| SCHEMBL3226638 | 0.83 | HPGDS (0.58) | HPGDSSCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL12084176 | 0.82 | HPGDS (0.70) | HPGDS | |
| SCHEMBL3217969 | 0.82 | HPGDS (0.61) | HPGDSSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885SCN9A 3307/4885SCN2B 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.